April 26, 2022

The Honorable Frank Pallone, Jr.  
2107 Rayburn House Office  
Washington, DC 20515

The Honorable Cathy McMorris Rodgers  
1035 Longworth House Office Building  
Washington, DC 20515

The Honorable Richard Neal  
372 Cannon House Office Building  
Washington, DC 20515

The Honorable Kevin Brady  
1011 Longworth House Office Building  
Washington, DC 20515

Dear Chairmen Pallone and Neal, Ranking Members McMorris Rodgers and Brady,

On behalf of the 72 organizations signed below; we request your respective committees hold a hearing to consider The Facilitating Innovative Nuclear Diagnostics (FIND) Act of 2021 (H.R. 4479).

Improving health outcomes often starts with early and accurate diagnosis. Recent innovations in nuclear medicine now allow physicians a safe, non-invasive way to gather specific medical information that would otherwise be unavailable or only available through surgery.

With each passing year, newer, more precise diagnostic radiopharmaceuticals are used in nuclear medicine procedures, which aid clinicians ability to diagnose and plan the most effective treatment pathway for diseases, such as Alzheimer’s, Parkinson’s, advanced cardiovascular, and cancers of the prostate, neuroendocrine system and breast. All diagnostic radiopharmaceuticals are statutorily considered drugs but are treated as supplies by the Centers of Medicare & Medicaid Services (CMS).

20 million Americans benefit from nuclear medicine procedures annually, but more can be done to increase access to advanced nuclear diagnostic tests, which can provide for more accurate diagnosis and treatment plans, saving both the patient and Medicare from unnecessary or inappropriate testing. It is especially critical now that better nuclear medicine therapies are also available to patients. Oftentimes, the only thing standing in between the patient and the nuclear medicine therapeutic is access to the appropriate PET scan. H.R. 4479 is a bipartisan, bicameral, budget neutral legislation that would direct CMS to pay separately for all diagnostic radiopharmaceuticals with a per day cost that exceeds $500 and were FDA-approved on or after January 1, 2008. This policy will safeguard Medicare beneficiary access to the most appropriate diagnostic radiopharmaceuticals and help spur continued innovations in nuclear imaging studies.

To help advance this legislation, we again respectfully ask that your committees hold a hearing to consider the FIND Act and explore the potential of this policy to expand beneficiary access to care, improve health outcomes, create healthcare savings and promote innovation and development in this space.

Sincerely,

AdMeTech Foundation
Advanced Accelerator Applications, a Novartis Company
Alamo Breast Cancer Foundation
Alliance for Aging Research
American College of Nuclear Medicine
American College of Radiology
American Society of Neuroradiology
American Society of Radiologic Technologists
AnCan Foundation
Arizona Prostate Cancer Coalition, Inc.
Biogen
Blue Earth Diagnostics
Bracco Diagnostics
Brian Grant Foundation
Cancer ABCs
Carcinoid Cancer Foundation
Cardinal Health Nuclear & Precision Health Solutions
Cerveau Technologies, Inc.
Clarity Pharmaceuticals
Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR)
Curium
Dallas Area Parkinsonism Society
Davis Phinney Foundation
Eckert & Ziegler Isotope Products
Eckert & Ziegler Radiopharma, Inc.
Eden Radioisotopes, LLC
FORCE: Facing Our Risk of Cancer Empowered
GE Healthcare Pharmaceutical Diagnostics
GO2 Foundation for Lung Cancer
Hawai‘i Parkinson Association
Healing NET Foundation
Houston Area Parkinson Society
International Isotopes, Inc
Ionetix
Jubilant Radiopharma
Lantheus Holdings, Inc.
Life Molecular Imaging
Los Angeles Carcinoid Neuroendocrine Tumor Society
Mayo Clinic Department of Radiology
Medical Imaging &Technology Alliance (MITA)
MedTrace
METAvivor
The Michael J. Fox Foundation for Parkinson’s Research
National Alliance of State Prostate Cancer Coalitions
National Association of Nuclear Pharmacies
Navidea Biopharmaceuticals, Inc
Neuroendocrine Tumor Research Foundation
NorCal CarciNET Community
Northern California PET
NorthStar Medical Technologies, LLC
Northwest Parkinson’s Foundation
Optimal Tracers
The Parkinson Alliance
Parkinson Association of Northern California
Parkinson Association of the Rockies
Parkinson's Foundation
Parkinson & Movement Disorders Alliance
The Parkinson's Unity Walk
PharmaLogic
Pheo Para Alliance
Power for Parkinson's
Prostate Conditions Education Council
RetireSafe
SHINE Technologies, LLC
Siemens Healthiness
Society of Nuclear Medicine & Molecular Imaging (SNMMI)
SOFIE
Sun Radiopharma.
Telix Pharmaceuticals, Inc.
TerraPower Isotopes
Veterans Prostate Cancer Awareness, Inc.
ZERO- The End of Prostate Cancer